Disease · MONDO_0002087
peritoneum cancer
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. peritoneum cancer. Diseases, record MONDO_0002087. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002087
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- cancer of peritoneum, cancer of the peritoneum, malignant neoplasm of peritoneum, malignant peritoneal neoplasm, malignant peritoneum neoplasm, peritoneal cancer, peritoneal cavity cancer
- Open Targets
Drugs88
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| NIRAPARIB TOSYLATE MONOHYDRATE | CHEMBL3989922 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 3 | ClinicalTrials.gov | 29 | 29 | 29 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 28 | 28 | 28 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Phase 3 | ClinicalTrials.gov | 22 | 22 | 22 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| OLAPARIB | CHEMBL521686 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| DOXORUBICIN | CHEMBL53463 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 5 | Drugs and targets |
| DOXORUBICIN HYDROCHLORIDE | CHEMBL359744 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 5 | Drugs and targets |
| PEMBROLIZUMAB | CHEMBL3137343 | Antibody | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| GEMCITABINE | CHEMBL888 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
1 to 10 of 88
See all 88 drugsTargets129
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| FLT4 | Vascular endothelial growth factor receptor | 6 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 6 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 5 | Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 5 | Stem cell growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PARP1 | PARP 1, 2 and 3 | 5 | PARP 1, 2 and 3 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor | Approval | https://conductscience.org/library/genes/142 | Drugs and targets |
| PARP2 | PARP 1, 2 and 3 | 5 | PARP 1, 2 and 3 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor | Approval | https://conductscience.org/library/genes/10038 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 5 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| TOP1 | DNA topoisomerase 1 | 5 | DNA topoisomerase I inhibitor | Phase 3 | https://conductscience.org/library/genes/7150 | Drugs and targets |
| TUBA1A | Tubulin | 4 | Tubulin inhibitor; Tubulin stabiliser | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 4 | Tubulin inhibitor; Tubulin stabiliser | Phase 3 | https://conductscience.org/library/genes/10376 | Drugs and targets |
1 to 10 of 129
See all 129 targetsTrials105
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00108745 | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer | Phase 3 | 1,157 | 2021-04-01 | Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7 | PACLITAXEL, PACLITAXEL POLIGLUMEX | Its record names the disease | ClinicalTrials.gov |
| NCT00954174 | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer | Phase 3 | 637 | 2020-08-10 | Mixed Mesodermal (Mullerian) Tumor, Ovarian Carcinosarcoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage I Ovarian Cancer AJCC v6 and v7, Stage IA Fallopian Tube Cancer AJCC v6 and v7, Stage IA Ovarian Cancer AJCC v6 and v7, Stage IA Uterine Sarcoma AJCC v7, Stage IB Fallopian Tube Cancer AJCC v6 and v7, Stage IB Ovarian Cancer AJCC v6 and v7, Stage IB Uterine Sarcoma AJCC v7, Stage IC Fallopian Tube Cancer AJCC v6 and v7, Stage IC Ovarian Cancer AJCC v6 and v7, Stage IC Uterine Sarcoma AJCC v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIA Uterine Sarcoma AJCC v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIB Uterine Sarcoma AJCC v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIA Uterine Sarcoma AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIB Uterine Sarcoma AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IIIC Uterine Sarcoma AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7, Stage IVA Uterine Sarcoma AJCC v7, Stage IVB Uterine Sarcoma AJCC v7, Uterine Carcinosarcoma | CARBOPLATIN, IFOSFAMIDE, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT05092360 | Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) | Phase 3 | 456 | 2025-08-28 | Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | PEMBROLIZUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02101788 | Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer | Phase 2/3 | 260 | 2020-09-29 | Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma | DOXORUBICIN, DOXORUBICIN HYDROCHLORIDE, LETROZOLE, PACLITAXEL, TAMOXIFEN, TOPOTECAN, TRAMETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01116648 | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | Phase 1/2 | 155 | 2020-07-22 | Fallopian Tube Carcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Triple-Negative Breast Carcinoma | CEDIRANIB MALEATE, OLAPARIB | Its record names the disease | ClinicalTrials.gov |
| NCT00170573 | Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer | Phase 2 | 77 | 2024-12-16 | Ovarian Cancer | DOXORUBICIN | Its record names the disease | ClinicalTrials.gov |
| NCT00278343 | Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer | Phase 2 | 74 | 2017-07-02 | Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer | CEDIRANIB | Its record names the disease | ClinicalTrials.gov |
| NCT00569673 | Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer | Phase 2 | 71 | 2014-06-26 | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer | DOCETAXEL, TRABECTEDIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00436215 | Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer | Phase 2 | 55 | 2015-03-26 | Ovarian Neoplasm, Fallopian Tube Cancer, Primary Peritoneal Cancer | BEVACIZUMAB, SORAFENIB | Its record names the disease | ClinicalTrials.gov |
| NCT01031381 | Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer | Phase 2 | 50 | 2016-08-30 | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | BEVACIZUMAB, EVEROLIMUS | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 105
See all 105 trialsComparisons in its trials10
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Regimen I - Uterine and Non-uterine Carcinosarcoma vs Regimen II - Uterine and Non-uterine Carcinsarcoma Subjects: deaths from any cause | 160 of 272 | 160 of 267 | 539 | NCT00954174 | Trial comparisons |
| Regimen I - Uterine and Non-uterine Carcinosarcoma vs Regimen II - Uterine and Non-uterine Carcinsarcoma Subjects: serious adverse events | 80 of 268 | 68 of 247 | 515 | NCT00954174 | Trial comparisons |
| Arm A - Control Arm vs Arm B - Experimental Arm: Objective Tumor Response Rate (Complete Response and Partial Response) | 8 of 130 | 34 of 130 | 260 | NCT02101788 | Trial comparisons |
| Arm A (MV-NIS) vs Arm B (DOXIL, GEM, TOPA, TAXOL): deaths from any cause | 8 of 10 | 5 of 7 | 17 | NCT02364713 | Trial comparisons |
| Arm A (MV-NIS) vs Arm B (DOXIL, GEM, TOPA, TAXOL): serious adverse events | 6 of 9 | 2 of 5 | 14 | NCT02364713 | Trial comparisons |
| Arm A (MV-NIS) vs Arm B (DOXIL, GEM, TOPA, TAXOL): Overall Survival | 4 of 8 | 2 of 5 | 13 | NCT02364713 | Trial comparisons |
| Arm A (MV-NIS) vs Arm B (DOXIL, GEM, TOPA, TAXOL): Objective Response Rate | 0 of 8 | 0 of 5 | 13 | NCT02364713 | Trial comparisons |
| Arm A (MV-NIS) vs Arm B (DOXIL, GEM, TOPA, TAXOL): Progression-free Survival | 5 of 8 | 4 of 5 | 13 | NCT02364713 | Trial comparisons |
| Arm A (MV-NIS) vs Arm B (DOXIL, GEM, TOPA, TAXOL): Incidence of Adverse Events Per Common Terminology Criteria for Adverse Events Version 4.0 | 3 of 8 | 2 of 5 | 13 | NCT02364713 | Trial comparisons |
| Phase 2: CRS-207/Pembro/IDO vs Phase 2: CRS-207/Pembro: Phase 2: Adverse Events (AEs) | 1 of 1 | 3 of 3 | 4 | NCT02575807 | Trial comparisons |
Papers from its trials61
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002087
GET https://conductscience.org/api/diseases/v1/MONDO_0002087/drugs?page=2